Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07503613 | Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy | enrolling by invitation | — | 100 | Akouos, Inc.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07703735 | Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma(HCC) | enrolling by invitation | — | 371 | Seoung Hoon KimOTHER_GOV | 0 | Jul 14, 2026 |
| clinicaltrials |
| NCT04996706 | Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO Study(LEO) | enrolling by invitation | — | 21,000 | Mayo ClinicOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06424626 | A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma | enrolling by invitation | Phase 1 | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06848088 | A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment | enrolling by invitation | Phase 2 | 48 | Regeneron PharmaceuticalsINDUSTRY | 2 | Jul 13, 2026 | clinicaltrials |
| NCT07690761 | Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant(Rituximab+ Zan) | enrolling by invitation | Phase 2 | 12 | Bnai Zion Medical CenterOTHER_GOV | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07139951 | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin and Paclitaxel for Gastric Cancer at High Risk of Peritoneal Recurrence | enrolling by invitation | Phase 2 | 16 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07267910 | Measuring Vestibular Organ Function With Weak Alternating Current Stimulation(VESTI) | enrolling by invitation | N/A | 30 | Aalto UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678047 | Leveraging Project ECHO for Improved Cervical Cancer Screening in Ethiopia | enrolling by invitation | N/A | 60 | Albert Einstein College of MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07499128 | Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event | enrolling by invitation | N/A | 136 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT02427269 | University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository(BEECAB) | enrolling by invitation | — | 1,000 | University of North Carolina, Chapel HillOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02600949 | Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer | enrolling by invitation | Phase 1 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07198945 | Six Versus Twelve Month Index Follow-up After Large Colon Polyp Resection(STARLING) | enrolling by invitation | N/A | 546 | Indiana UniversityOTHER | 3 | Jun 17, 2026 | clinicaltrials |
| NCT07651163 | Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 450 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651176 | Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 267 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT06985576 | Long-term Study to Evaluate Safety and Persistence of GF-CART01 | enrolling by invitation | — | 18 | GenomeFrontier Therapeutics TW Co., Ltd.INDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07186530 | Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening | enrolling by invitation | N/A | 500 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07634575 | Triggered Imaging in Glioblastoma Based on Clinical Outcome Evaluation Compared to Routine: a Feasibility Study(TIGER F) | enrolling by invitation | N/A | 20 | King's College Hospital NHS TrustOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07633353 | Real-World Outcomes of First-Line Treatment of Metastatic or Locally Advanced Upper Tract Urothelial Carcinoma With Enfortumab Vedotin Plus Pembrolizumab : A French Multicenter Retrospective Observational Study(UTUC PROVE) | enrolling by invitation | — | 50 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06967467 | Allergy Delabeling in Antibiotic Stewardship - Evaluations(RENEW-EVAL) | enrolling by invitation | — | 80 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT06744595 | Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer | enrolling by invitation | N/A | 50 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07621757 | The Implementation of Genetic Risk for Colorectal Cancer Screening(PRO-GENE-COLON) | enrolling by invitation | — | 100 | Endeavor HealthOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07618624 | BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression(BRIDGE) | enrolling by invitation | Phase 2 | 42 | Sun Yat-sen UniversityOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05116137 | The Impact of Resistance ExerciSe on Muscle Mass in GlioblaSToma Survivors(RESIST) | enrolling by invitation | N/A | 24 | Nova Scotia Health AuthorityOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT07606638 | Effectiveness of Opioid vs Pregabalin Plus Naproxen Sodium in Pain Management of Oral Cancer Patients | enrolling by invitation | N/A | 98 | Mayo Hospital LahoreOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT05418959 | Genetic Risk Stratification of Pediatric Skin Lesions | enrolling by invitation | Phase 1 | 100 | Massachusetts General HospitalOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07240857 | A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer | enrolling by invitation | Early Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07603167 | p-PHOTOLARYNX- ANTHEM: Photon-Counting CT in Laryngeal Cancer Staging(H&NRAD-2025-01) | enrolling by invitation | — | 60 | Humanitas UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06885424 | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products(DESCENT-1) | enrolling by invitation | — | 400 | A2 Biotherapeutics Inc.INDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT07595666 | Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region. | enrolling by invitation | N/A | 1,600 | prof. dr. Koen Van LaereOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06204614 | Drug Screening Using IMD in Bladder Cancer | enrolling by invitation | Early Phase 1 | 18 | Brigham and Women's HospitalOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06324110 | Evaluating the Impact of Centralized Interventions on Lung Cancer Screening Adherence in Community Settings, ACCELL Trial | enrolling by invitation | N/A | 6,772 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06782399 | Drug Screening of Cutaneous Lesions of Squamous Cell Carcinoma(SCC) | enrolling by invitation | Early Phase 1 | 25 | Oliver JonasOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07587411 | Stepped-Care Support for Children With Leukaemia(STEP-Leukemia) | enrolling by invitation | N/A | 96 | Zhengzhou UniversityOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07583160 | YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer(YS247) | enrolling by invitation | Phase 1 | 18 | Changhai HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06862479 | Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)(ES-LCCE-UDFM) | enrolling by invitation | — | 180 | Unidade Local de Saúde Santa MariaOTHER_GOV | 1 | May 6, 2026 | clinicaltrials |
| NCT07567716 | Infiltration Pattern of Locally Advanced ESCC | enrolling by invitation | — | 30 | Shanghai Chest HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07563335 | Stage-Matched Psychosocial Intervention for Parent Caregivers of Children With Leukemia in Pakistan(SMP-CLP) | enrolling by invitation | N/A | 88 | Zhengzhou UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06665490 | Pilot Study to Characterize the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of CLn® Skin Care Body Wash | enrolling by invitation | — | 15 | Northwestern UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07172191 | Fecal Microbiota Transplantation Among Adult Patients With Hematological Malignancies(HEMAT-FMT) | enrolling by invitation | N/A | 100 | Del-Pest Central Hospital - National Institute of Hematology and Infectious DiseasesOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07550582 | Mesenteric Vascular Preconditioning Combined With Laparoscopic and Endoscopic Cooperative Surgery for Submucosal Tumor at the Gastroesophageal Junction(SAVE-GEJ) | enrolling by invitation | Phase 2 | 40 | Peking University People's HospitalOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03054792 | Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas | enrolling by invitation | Phase 1 | 18 | The Hospital for Sick ChildrenOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06381882 | The Role of the Human Microbiome in Patients After Pancreatic Resection.(MiPac) | enrolling by invitation | — | 200 | St. Antonius HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07298577 | Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer(STOPHCC-GAAD) | enrolling by invitation | N/A | 2,100 | Siriraj HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07550972 | Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. | enrolling by invitation | Phase 2 | 30 | Zhejiang Provincial People's HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06281964 | Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.(KANNON-2) | enrolling by invitation | Phase 3 | 327 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06300502 | Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs) | enrolling by invitation | Phase 1 | 15 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07353294 | Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC | enrolling by invitation | Phase 1 | 12 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07542158 | Ultralow Dose PET Imaging of 18F-FDOPA | enrolling by invitation | Phase 2 | 200 | Akiva MintzOTHER | 1 | Apr 21, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 16, 2026source: clinicaltrials